SecBot SecBot
PRESS-RELEASE ·Filed Mar 18, 2026

RVPH

Reviva Pharmaceuticals
BEARISH
Impact 6/10
Horizonimmediate Processed8mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight ▼ Bearish

Traders should monitor for immediate downward pressure on RVPH shares due to dilution and the overhang from short-term exercisable warrants. The Series H warrants (12-month expiry) create near-term share supply risk if exercised or if investors sell into the market in anticipation.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.8300
T+0 close · Mar 18, 2026 · via day close
Latest settled
−15.66%
T+60 · $0.7000
Vs SPY
−30.01%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 19 $0.8300entry
  2. T+1 · 8mo ago −3.61%α −1.87% · $0.8000
  3. T+5 · 8mo ago −6.02%α −3.81% · $0.7800
  4. T+20 · 7mo ago +2.41%α −5.21% · $0.8500
  5. T+60 · 5mo ago −15.66%α −30.01% · $0.7000
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Reviva Pharmaceuticals (RVPH) announced the pricing of a public offering of 6,666,667 shares of common stock and accompanying warrants to raise approximately $10 million in gross proceeds. The funds will be used to support the Phase 3 RECOVER-2 trial for brilaroxazine in schizophrenia, along with general corporate purposes. The offering includes dual tranches of warrants exercisable immediately at $1.50 per share, with differing expiration terms.

Key Financial Metrics

Deal Value
$10.0M

Key Facts

  • Reviva is raising approximately $10 million through a public offering of 6,666,667 shares and warrants.
  • Each share is sold with two warrants: Series G (5-year term) and Series H (12-month term), both exercisable at $1.50.
  • The offering is priced at $1.50 per combined unit, below typical market thresholds for sustainable biotech financing.
  • Proceeds will fund the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia and general corporate needs.
  • A.G.P./Alliance Global Partners is the sole placement agent; closing expected March 20, 2026.

Financial Impact

Approximately $10 million in gross proceeds, with significant near-term dilution from short-term warrants.

dilutioncashequity_value

Risk Factors

  • High dilution risk from immediate exercisability of both warrant series, especially the 12-month Series H warrants.
  • Low offering price of $1.50 suggests weak investor demand or distressed financing terms.
  • Market cap of $14M indicates high risk of volatility and potential for further dilutive offerings.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3258719

Track record

12 reports on RVPH

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +22.98% at T+20 after the Jul 10, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 3/10 No price data
  2. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.3400 Now $0.3504 +3.07% settles Feb 11
  3. Nov 9, 20267d ago DEF 14A Neutral 4/10 Entry $0.3521 Now $0.3504 −0.47% settles Feb 8
  4. Aug 12, 202613w ago Press Release Neutral 4/10 Entry $0.3521 to $0.3521 Now $0.3504 −0.47% · 0.00% +5.48% vs SPY
  5. Jul 10, 202618w ago 25-NSE Bearish 7/10 Entry $0.6200 to $0.5000 Now $0.3504 +43.48% ▲ +19.35% +22.24% vs SPY
  6. May 13, 202626w ago Press Release Bearish 7/10 Entry $0.3900 to $0.4303 Now $0.3504 +10.14% ▼ −10.33% −6.74% vs SPY
  7. May 13, 202626w ago 8-K Bearish 8/10 Entry $0.3521 to $0.4775 Now $0.3504 +0.47% ▼ −35.62% −31.19% vs SPY
  8. Apr 15, 202630w ago 8-K Neutral 5/10 Entry $0.8900 to $0.5731 Now $0.3504 −60.62% ▼ −35.61% −43.74% vs SPY
  9. Mar 30, 202633w ago Press Release Mixed 6/10 Entry $0.6600 to $0.6000 Now $0.3504 −46.90% ▼ −9.09% −25.58% vs SPY
  10. Mar 18, 202634w ago Press Release Bearish 6/10 Viewing Entry $0.8300 to $0.7000 Now $0.3504 +57.78% ▲ +15.66% +30.01% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (11h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 18, 2026